Urol. praxi. 2017;18(4):148-153 | DOI: 10.36290/uro.2017.035

Pharmacotherapy treatment of urge incontinence and overactive bladder in elderly people

prof. MUDr. Eva Topinková, CSc.
Geriatrická klinika 1. LF UK a VFN, Praha

Overactive bladder, characterized by episodes of urgency, micturition frequency, nycturia and, in majority of patients urge incontinenceaffect 20–30% of seniors 70 years and over. The treatment of choice are antimuscarininc drugs which consistently proveantimuscarinics superiority over placebo comparably so as in middle age. In old age due to the physiologic age-associated organchanges, frequent commorbidities and polypharmacotherapy antimuscarinics with higher tissue selectivity are recommended,which do not cross blood-brain barrier and those with low risk of drug interactions. Extended release formulations with lowerrates of AE are preferred. Scientific evidence and Incontinence Guidelines of EAU 2017 are presented with special focus on old age.

Keywords: overactive bladder, urgency, urge incontinence, elderly, pharmacotherapy, antimuscarinic drugs

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Topinková E. Pharmacotherapy treatment of urge incontinence and overactive bladder in elderly people. Urol. praxi. 2017;18(4):148-153. doi: 10.36290/uro.2017.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009; 103(2): 202-209. Go to original source... Go to PubMed...
    2. Zmrhal J, Topinková E, Zmrhalová B. Inkontinence moči u žen v seniu: Limity diagnostiky a léčby. Česká geriatrická revue 2006; 4(4): 189-200.
    3. Topinková E. Hyperaktivní měchýř ve stáří a možnosti léčby v primární péči. Med. praxi. [Online]. 2012; 9(1): 20-24 [Cit. 2017-07-19]. Dostupné z: http://www.solen.cz/pdfs/med/2012/01/05.pdf.
    4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-1314. Go to original source... Go to PubMed...
    5. Abrams P, Cardozo L, Fall M, et al. For the Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract fimction: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21: 167-178. Go to original source... Go to PubMed...
    6. Horčička L, Zachoval R, Vlková J, Moravčíková D, Topinková E. Diagnostika a léčba močové inkontinence u žen. Novelizace 2017, Centrum doporučených postupů pro praktické lékaře, SVL ČLS JEP, 2017.
    7. Krhut J. Hyperaktivní močový měchýř, Maxdorf, Praha 2007.
    8. Brown J, Vittinghof E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? J Am Geriatr Soc. 2000; 48: 721-725. Go to original source... Go to PubMed...
    9. Horčička L, Bojar M, Pastor Z, Topinková E, Vlková J, Zachoval R. Inkontinence moči v každodenní praxi, Mladá fronta a.s., 2017.
    10. Verner P. Farmakologická léčba hyperaktivního močového měchýře a urgentní inkontinence. Farmakoterapie 2007; 3(5): 513-522.
    11. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urolog. pro Praxi. [Online]. 2010; 11(5): 241-246 [Cit. 2017-07-19]. Dostupné z: http://www.solen.cz/pdfs/uro/2010/05/04.pdf.
    12. Kachlířová Z, Horčička L. Hyperaktivní močový měchýř - možnosti léčby v roce 2012. Remedia. [Online]. 2012; 22(5): 320-326 [Cit. 2017-07-19]. Dostupné z: http://www.remedia.cz/Archiv-rocniku/Rocnik-2012/5-2012/Hyperaktivni-mocovy-mechyr-moznosti-lecby-v-roce-2012/e-1dQ-1lK-1lM.magarticle.aspx.
    13. Staskin DR: Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005; 22: 1013-1028. Go to original source... Go to PubMed...
    14. Topinková E. Úskalí farmakologické léčby urgentní inkontinence a hyperaktivního měchýře ve stáří. Lékařské listy ZN, 2009, 18, příloha ze 2. 11. 2009: 21-24.
    15. Burkhard FC, Bosch JLHR, Cruz F, et al. Guidelines from the European Association of Urology (EAU) Working Panel on Urinary Incontinence [Cit. 2017-07-19]. Dostupné z: https://uroweb.org/guideline/urinary-incontinence/#4.
    16. Higgins J, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, 2016. [Cit. 2017-07-19]. Dostupné z: http://training.cochrane.org/handbook.
    17. Reynolds WS, et al. Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis. Obstet Gynecol, 2015; 125: 1423-1432. Go to original source... Go to PubMed...
    18. Shamliyan T, et al. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. 2012, IUGA-ICS Conservative Management for Female Pelvic Floor Dysfunction: Rockville (MD).
    19. Rai BP, et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev, 2012. 12: CD003193. Go to original source... Go to PubMed...
    20. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn, 2014; 33: 17-30. Go to original source... Go to PubMed...
    21. Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol, 2014. 46: 275-284. Go to original source... Go to PubMed...
    22. Wu T, Duan X, Cao CX, et al. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int, 2014; 93: 326-337. Go to original source... Go to PubMed...
    23. Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol, 2014; 65: 755-765. Go to original source... Go to PubMed...
    24. Topinková E. Farmakoterapie hyperaktivního močového měchýře ve stáří. Medicína po promoci 2010; 11(Suppl. 1): 36-44.
    25. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med, 2015; 175: 401-407. Go to original source... Go to PubMed...
    26. Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol, 2016; 73: 721-732. Go to original source... Go to PubMed...
    27. Topinková E. Nežádoucí účinky antimuskarinik na centrální nervový systém. Urol listy 2012; 10(1): 69-74.
    28. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005; 27(2): 144-153. selective receptor antagonist. Eur Urol 2005; 48: 471-477. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.